ID: h-16ae38923d
Hypothesis
Endosomal-Retromer Trafficking Defect as a Shared Sorting Failure
Disrupted retrieval of cargo from endosomes to the trans-Golgi network (retromer dysfunction) impairs processing of APP, α-synuclein trafficking, and TDP-43 clearance.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Disrupted retrieval of cargo from endosomes to the trans-Golgi network (retromer dysfunction) impairs processing of APP, α-synuclein trafficking, and TDP-43 clearance. SORL1 variants increase AD risk; VPS35 D620N causes familial PD. The mechanism represents one of the cleaner intersections between AD and PD. However, less convincing for ALS/FTD and no mature clinical precedent exists. Best development path is genetically enriched AD/PD subsets rather than pan-NDD indication.
🧬 Mechanism
🔗 Mechanism from KG for VPS35, VPS26, SORL1, SNX27
Auto-built from this analysis's top knowledge-graph edges.
graph TD
GBA1_mutations["GBA1 mutations"] -->|increases risk| PD["PD"]
TREM2_R47H_variant["TREM2 R47H variant"] -->|increases risk| Ad["Ad"]
alpha_synuclein_fibrils["alpha-synuclein fibrils"] -->|activates| NLRP3_Inflammasome["NLRP3 Inflammasome"]
TFEB_overexpression["TFEB overexpression"] -.->|inhibits| tau_A__pathology["tau/Aβ pathology"]
TARDBP_MUTATIONS["TARDBP MUTATIONS"] -->|causes| ALS_FTD["ALS/FTD"]
TDP_43_INCLUSIONS["TDP-43 INCLUSIONS"] -->|associated with| ALS_FTD_1["ALS/FTD"]
NfL_reduction["NfL reduction"] -->|biomarker for| als["als"]
TARDBP["TARDBP"] -->|cross disease mech| ALS["ALS"]
TARDBP_2["TARDBP"] -->|cross disease mech| FTD["FTD"]
TARDBP_3["TARDBP"] -->|cross disease mech| AD_LATE["AD/LATE"]
h_cross_synth_tdp43_rna_p["h-cross-synth-tdp43-rna-proteostasis"] -->|proposes shared me| TARDBP_4["TARDBP"]
SNCA["SNCA"] -->|cross disease mech| PD_5["PD"]
style GBA1_mutations fill:#ce93d8,stroke:#333,color:#000
style PD fill:#ef5350,stroke:#333,color:#000
style TREM2_R47H_variant fill:#ce93d8,stroke:#333,color:#000
style Ad fill:#ef5350,stroke:#333,color:#000
style alpha_synuclein_fibrils fill:#4fc3f7,stroke:#333,color:#000
style NLRP3_Inflammasome fill:#ce93d8,stroke:#333,color:#000
style TFEB_overexpression fill:#4fc3f7,stroke:#333,color:#000
style tau_A__pathology fill:#4fc3f7,stroke:#333,color:#000
style TARDBP_MUTATIONS fill:#ce93d8,stroke:#333,color:#000
style ALS_FTD fill:#ef5350,stroke:#333,color:#000
style TDP_43_INCLUSIONS fill:#4fc3f7,stroke:#333,color:#000
style ALS_FTD_1 fill:#ef5350,stroke:#333,color:#000
style NfL_reduction fill:#ce93d8,stroke:#333,color:#000
style als fill:#ef5350,stroke:#333,color:#000
style TARDBP fill:#4fc3f7,stroke:#333,color:#000
style ALS fill:#ef5350,stroke:#333,color:#000
style TARDBP_2 fill:#4fc3f7,stroke:#333,color:#000
style FTD fill:#ef5350,stroke:#333,color:#000
style TARDBP_3 fill:#4fc3f7,stroke:#333,color:#000
style AD_LATE fill:#ef5350,stroke:#333,color:#000
style h_cross_synth_tdp43_rna_p fill:#4fc3f7,stroke:#333,color:#000
style TARDBP_4 fill:#4fc3f7,stroke:#333,color:#000
style SNCA fill:#4fc3f7,stroke:#333,color:#000
style PD_5 fill:#ef5350,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Supports
Retromer protein levels reduced in AD brain; VPS35 overexpression reduces Aβ in mice
Contradicts
VPS35 gene therapy or overexpression is too early and safety-sensitive
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — VPS35
No curated PDB or AlphaFold mapping for VPS35 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for VPS35, VPS26, SORL1, SNX27.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.8%
Volatility
Low
0.0019
Events (7d)
3
Price History
▼12.1%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF skin fibroblasts from VPS35 D620N mutation carriers (familial PD) are stratified against age-matched sporadic PD and healthy controls, THEN VPS35 protein expression will be reduced by ≥40% and endo | ≥40% reduction in VPS35 protein by quantitative western blot; ≥50% delayed clearance of transferrin receptor (endosomal recycling marker) by live-cell imaging. | — no observation — | pending | 0.58 |
| IF human iPSC-derived neurons harboring SORL1 missense risk variants are treated with a VPS26/VPS35 retromer-complex stabilizer (e.g., pharmacological chaperone at 10μM for 14 days), THEN secreted Aβ4 | ≥30% reduction in Aβ42/Aβ40 ratio in conditioned media, measured by multiplexed immunoassay (Electrochemiluminescence). | — no observation — | pending | 0.62 |
🔮 Falsifiable Predictions (2)
pendingconf 62%
IF human iPSC-derived neurons harboring SORL1 missense risk variants are treated with a VPS26/VPS35 retromer-complex stabilizer (e.g., pharmacological chaperone at 10μM for 14 days), THEN secreted Aβ42/Aβ40 ratio will decrease by ≥30% compared to vehicle-treated isogenic controls within 4 weeks.
Predicted outcome: ≥30% reduction in Aβ42/Aβ40 ratio in conditioned media, measured by multiplexed immunoassay (Electrochemiluminescence).
Falsification: No statistically significant change in Aβ42/Aβ40 ratio (p>0.05, two-tailed t-test) between retromer-stabilizer and vehicle conditions in SORL1 variant neurons.
pendingconf 58%
IF skin fibroblasts from VPS35 D620N mutation carriers (familial PD) are stratified against age-matched sporadic PD and healthy controls, THEN VPS35 protein expression will be reduced by ≥40% and endosomal cargo周转率 will be impaired by ≥50% within 3 months.
Predicted outcome: ≥40% reduction in VPS35 protein by quantitative western blot; ≥50% delayed clearance of transferrin receptor (endosomal recycling marker) by live-cell
Falsification: VPS35 protein levels and endosomal trafficking kinetics are statistically indistinguishable between VPS35 D620N carriers and sporadic PD/controls (p>0.05 by ANOVA with Bonferroni correction).
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.